Voeding en voedingstoffen en effect bij leverkanker: Menatetrenone ( = analoog aan vitamine K2) vermindert bij operabele leverkanker de kans op een recidief significant - 42,7 % na 1 jaar en 27,3% na 3 jaar ) en verbetert 3 jaars overleving met 23 %. Nieuwe meta analyse bevestigt resultaten. Artikel update 15 oktober 2011
15 oktober 2011: Onderaan heb ik het abstract van een recentere studie naar effect van menatetrenone ( vitamine K2) bij levertumoren geplaatst. Met zelfde positieve resultaten als uit onderstaande studie blijkt uit maart 2006.
22 maart 2006: Bron: SOURCE: Cancer 2006;106:867-872
Menatetrenone ( = analoog aan vitamine K2) vermindert bij operabele leverkanker de kans op een recidief significant met na 1 jaar 42,7 % en na drie jaar 27,3% en verbetert 3 jaars overleving met 23 %. Wij vertaalden voor u het volledige persbericht van Reuters over deze studie.
Menatetrenone verbetert significant behandelingen van leverkanker
NEW YORK MAT 16, 2006 (Reuters Health) - Voor patiënten die een curatieve - genezende behandeling hebben gekregen voor hun leverkanker (HCC) vermindert menatetrenone (een medicijn analoog aan vitamine K2) recidieven en verbetert significant de overleving, aldus tonen de resultaten uit een gerandomiseerde pilotstudie.
Menatetrenone is een analoog van vitamine K2, welke eerder aantoonde antiproliferatieve effecten te geven tegen leukemie en levercellijnen verklaren de auteurs.
Dr. Toshihiko Mizuta en collega's van de Saga Medical School, Japan, onderzochten de effecten van menatetrenone (analoog aan vitamine K2) op terugkeer van de ziekte en overleving bij 61 patiënten met HCC - primaire leverkanker, welke een operatie of percutane lokale ablatie therapie (TACE en/of RFA) hadden gehad.
Het vervolgens optredende recidief van HCC in de menatetrenone groep was 12.5% na 12 maanden, 39.0% na 24 maanden, en 64.3% na 36 maanden, vergeleken met 55.2%, 83.2%, en 91.6%, respectievelijk, in de placebo groep, aldus de auteurs.
De uiteindelijke overlevingscijfers waren ook beduidend hoger in de menatetrenone groep dan in de placebo groep (100% versus 96.4% na 12 maanden, 96.6% versus 80.9% na 24 maanden, en 87.0% versus 64% na 36 maanden), meldt het studieverslag.
Menatetrenone toediening werd niet geassocieerd met bijwerkingen, rapporteren de onderzoekers in de 15 februari editie van Cancer en geen enkele patiënt is met de studie gestopt tijdens de follow-up studie periode van mediaan 28,9 maanden Menatetrenone was effectief (profijtelijk) voor patiënten onafhankelijk van de basiswaarden van des-gamma-carboxy-prothrombin (een mogelijke marker van agressievere tumoren welke worden onderdrukt door toediening van vitamine K2), tonen de resultaten aan. "De resultaten van deze gerandomiseerde pilot studie wijst uit dat menatetrenone mogelijk het risico op een recidief van HCC - leverkanker vermindert na operatie of lokale ablatieve ingreep," concluderen de auteurs. "Het effect op overleving vergt wel nadere studies; Echter, al bij al, chemopreventie van een recidief van HCC - leverkanker door gebruik van menatetrenone - vit. K2 lijkt een beloftevolle optie".
SOURCE: Cancer 2006;106:867-872.
Menatetrenone Improves Hepatocellular Carcinoma Outcome
NEW YORK MAT 16, 2006 (Reuters Health) - For patients who have received curative treatment for hepatocellular carcinoma (HCC),menatetrenone reduces recurrences and improves survival, the results of a pilot study suggest.
Menatetrenone is an analog of vitamin K2, which has been shown to have antiproliferative effects against leukemia and hepatoma cell lines, the authors explain. Dr. Toshihiko Mizuta and colleagues from Saga Medical School, Japan, investigated the effects of menatetrenone on disease recurrence and survival in 61 patients with HCC after they underwent curative resection or percutaneous local ablation therapy.
The cumulative incidence of HCC recurrence in the menatetrenone group was 12.5% at 12 months, 39.0% at 24 months, and 64.3% at 36 months, the authors report, compared with 55.2%, 83.2%, and 91.6%, respectively, in the placebo group. Survival rates were also higher in the menatetrenone group than in the placebo group (100% versus 96.4% at 12 months, 96.6% versus 80.9% at 24 months, and 87.0% versus 64% at 36 months), the report indicates. Menatetrenone treatment was not associated with any adverse effects, the researchers report in the February 15th issue of Cancer, and no patient was withdrawn from the study during an average 28.9 months of follow-up. Menatetrenone was beneficial in patients regardless of the baseline level of des-gamma-carboxy-prothrombin (a possible marker of more aggressive tumors that is suppressed by vitamin K2 administration), the results indicate. "The results from this randomized, controlled, pilot study revealed that menatetrenone possibly may reduce the risk of HCC recurrence after curative surgical resection or local ablation therapy," the authors conclude. "The effect on survival warrants further research; however, overall, chemoprevention of secondary HCC using menatetrenone appears to be a promising option."
SOURCE: Cancer 2006;106:867-872.
Vitamin analogues in chemoprevention of hepatocellular carcinoma after resection or ablation--a systematic review and meta-analysis
Vitamin analogues in chemoprevention of hepatocellular carcinoma after resection or ablation--a systematic review and meta-analysis.
Source
Department of Oncology Comprehensive Treatment, Eastern Hepatobiliary Surgical Hospital, Second Military Medical University, 225 Changhai Road, Shanghai, China.
Abstract
OBJECTIVE:
While hepatic resection or local ablative therapy may provide a potentially curative treatment for hepatocellular carcinoma (HCC), more than half of these patients develop recurrent HCC within 5 years after treatment. Thus identification of any therapy which can decrease or delay the incidence of recurrence will improve the results of treatment. However, no chemopreventive agent has been approved for HCC.
METHODS:
A MEDLINE database, Embase, Cancerlit (National Cancer Institute), and CBM (Chinese Biomedical Database) search from 1990 to 2009 was performed to identify relevant articles using the keywords "hepatocellular carcinoma," "vitamin analogue," and "chemoprevention." Additional papers were identified by a manual search of the references from the key articles. The fixed effect model was used for a meta-analysis.
RESULTS:
Oral administration of acyclic retinoids (vitamin A analogue), and menatetrenone (vitamin K2 analogue) have been tested as chemopreventive agents after hepatic resection or local ablative therapy for HCC. There were one and four randomised, controlled trials (RCTs) which evaluated the efficacy of polyprenoic acid and menatetrenone, respectively. All studies were conducted in Japan. One RCT showed the preventive effect of polyprenoic acid in lowering the incidence of HCC recurrence after hepatic resection or percutaneous ethanol injection, and this effect lasted up to 199 weeks after randomization (or 151 weeks after completion of retinoid administration). Four RCTs evaluated the preventive efficacy of menatetrenone on HCC recurrence after hepatic resection or local ablative therapy. The results of three studies, as well as the meta-analysis of all four studies, showed significantly better tumour recurrence-free survival. The beneficial effect on the overall survival was less definite.
CONCLUSION:
There is evidence to suggest that chemopreventive therapy after partial hepatectomy or local ablative therapy is beneficial in prolonging disease-free survival, but the evidence is less for an effect on the overall survival. To confirm the beneficial role of vitamin A or K analogues in the chemoprevention of HCC further and larger randomised trials are now required.
Copyright © 2010 Asian Surgical Association. Published by Elsevier B.V. All rights reserved.
- PMID:
- 21163409
- [PubMed - indexed for MEDLINE]
